Parkedale Fluogen
Executive Summary
Production resumes at King's Parkedale facility April 13 after the company provides written certification to FDA that it has completed corrective action for cGMP deviations. Resumption of distribution of the flu vaccine will depend on FDA reinspection of Parkedale's facilities (1"The Pink Sheet" March 20, p. 27)